Top Stock Reports for Tesla, Home Depot & Boston Scientific

Wednesday, March 26, 2025The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), The Home Depot, Inc. (HD) and Boston Scientific Corp. (BSX), as well as two micro-cap stocks Frequency Electronics, Inc. (FEIM) and Bridger Aerospace Group Holdings, Inc. (BAER). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today’s research reports here >>>Ahead of Wall StreetThe daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.You can read today's AWS here >>> Pre-Markets Stay Flat a Week Ahead of TariffsToday's Featured Research ReportsTesla’s shares have outperformed the Zacks Automotive - Domestic industry over the past year (+59.7% vs. +14%). The company’s electric vehicle (EV) business is under pressure from pricing challenges and fierce competition, with 2024 marking its first-ever annual delivery decline. CEO Musk’s divided attention and growing political controversies have investors questioning whether Tesla is still his top priority. Further, Tesla expects operating expenses to rise this year, squeezing profitability. Having said that, Tesla's long-term growth prospects remain strong, driven by its thriving Energy Generation & Storage segment, expansive Supercharger network and AI advancements. Tesla’s robust balance sheet, with a high liquidity buffer, supports continued innovation and expansion. Progress in the autonomous vehicle domain, including plans to launch robotaxi services in 2025 bode well. Thus, investors should retain Tesla stock for now. (You can read the full research report on Tesla here >>>)Shares of Home Depot have declined -3.8% over the past year against the Zacks Retail - Home Furnishings industry’s decline of -6.9%. The company’s stocks are driven by a top-line recovery, supported by SRS contributions, stronger-than-expected demand, broad-based category growth, and positive Pro sales. Home Depot delivered better-than-expected sales and EPS in fourth-quarter fiscal 2024, with year-over-year improvements. The company is advancing its "One Home Depot" plan, focusing on supply chain expansion, technology investments, and digital enhancements. The interconnected retail strategy remains a key growth driver, ensuring a seamless shopping experience. HD expects the business momentum from late 2024 to carry into 2025. However, HD continues to see soft engagement for big-ticket discretionary categories, resulting in soft sales. Also, higher interest rates, soft margins and ongoing macroeconomic uncertainties pose risks.(You can read the full research report on Home Depot here >>>)Boston Scientific’s shares have outperformed the Zacks Medical - Products industry over the past year (+48.1% vs. +8.3%). The company is seeing strength across target markets despite macroeconomic concerns and related cost inflation. Strong worldwide demand for its MedSurg and Cardiovascular lines, traction in United States and outside for its the next generation WATCHMAN FLX and FLX Pro, as well as contribution from accretive acquisitions are important drivers. The Pain and Brain franchisees are expected to gain solid traction in 2025 banking on strong execution of core growth strategies. The Electrophysiology arm continues to gain momentum on sustained adoption of FARAPULSE PFA. The 2025 guidance indicating strong organic growth over 2024 builds confidence in the stock. On the flip side, mounting costs due to worldwide geopolitical issues are major concerns. FX headwinds are expected to impact the company’s top line in 2025.(You can read the full research report on Boston Scientific here >>>)Shares of Frequency Electronics have outperformed the Zacks Instruments - Control industry over the past year (+70.1% vs. -2%). This microcap company with market capitalization of $157.24 million has delivered a strong performance, with revenues rising 25.5% to $49.8 million and net income rising to $20.5 million for the nine months ended Jan. 31, 2025, driven by satellite program momentum. Gross margin expanded to 45.4% on improved execution and mix. A $73 million funded backlog (65% convertible in 12 months) supports near-term visibility, reinforced by $23 million in recent contract wins for aerospace and defense applications. Satellite-related revenues now comprise 58% of total sales, reflecting successful penetration into high-growth space markets. FEIM is also investing in quantum sensing aligned with U.S. defense priorities. However, risks include a $1.3 million operating cash outflow, declining cash reserves and a shrinking backlog. Heavy reliance on government contracts and minimal commercial exposure further constrain long-term resilience.(You can read the full research report on Frequency Electronics here >>>)Bridger Aerospace’s shares have underperformed the Zacks Aerospace - Defense industry over the past year (-75.1% vs. -3.7%). This microcap company with market capitalization of $65.06 million is facing risks which include high debt, seasonal revenue concentration, low backlog visibility and rising maintenance costs. International expansion and tech-focused acquisitions offer diversification, though execution risk remains. BAER is currently undervalued relative to its industry peers, with potential for growth if fundamentals continue to improve. Nevertheless, Bridger Aerospace posted record 2024 results, with revenues rising 47.8% to $98.6 million and adjusted EBITDA reaching $37.3 million. The company also achieved a positive operating cash flow of $9.4 million for the first time. Structural shifts toward year-round operations, driven by extended wildfire seasons, are expanding its revenue base. It operates the only U.S. fleet of Super Scoopers in a supply-constrained market, supported by long-term government contracts and new international growth via Spanish Scoopers. (You can read the full research report on Bridger Aerospace here >>>)Other noteworthy reports we are featuring today include iRobot Corp. (IRBT), Regeneron Pharmaceuticals, Inc. (REGN) and Manulife Financial Corp. (MFC).Mark VickerySenior EditorNote: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>Today's Must ReadCharging Business to Aid Tesla (TSLA) Amid Rising ExpensesHome Depot's (HD) Interconnected Strategy to Propel SalesSolid EP Gains, Acquisitions Boost Boston Scientific (BSX)Featured ReportsSolid Product Offerings Aids iRobot (IRBT) Amid Forex woesPer the Zacks analyst, iRobot Corporation's solid product offering like Roomba Combo 10 Max and Roomba Essential robots will continue to lend momentum to the company. Forex woes are an added concern.Dupixent Profits Fuels Regeneron (REGN), Eylea Decline A WoePer the Zacks analyst, stellar performance of Dupixent fuels Regeneron even as lead drug Eylea faces challenges. The company's progress with the oncology portfolio is also impressive.Solid Asia Operation Aid Manulife (MFC), High Expenses AilPer the Zacks analyst, Manulife is set to grow on strong Asian business as well as expansion of Wealth and Asset Management business. However, increase in expenses weighing on margin concern.Delta (DAL) Strong on Dividends Despite High Labor CostsThe Zacks Analyst is impressed by DAL's efforts to reward its shareholders. Escalated expenses on labor represent a concern.Strength in IOS & AHS Bodes Well For Fortive Amid China WoesPer the Zacks analyst, Fortive is witnessing momentum across Intelligent Operating Solutions and Advanced Healthcare segments. Unfavourable foreign currency and China headwind remain a concern.Increasing Orders Drive Textron (TXT), Amid Labor ShortagePer the Zacks analyst, Embraer is likely to benefit from increasing orders for its Aviation unit and higher aftermarket volume. Yet labor shortage result in delays and likely impact operating results.Built-to-Order Strategy Aids KB Home (KBH), High Costs AilPer the Zacks analyst, KB Home benefits from its Build-to-Order model and aggressive land acquisition strategy. However, mortgage rate pressures and high costs are concerns.New UpgradesStrength Across Outdoor & Fitness Segments Aid Garmin (GRMN)Per the Zacks analyst, Garmin is riding on solid demand for adventure watches and advanced wearables which is driving the performance of its Outdoor and Fitness segments.Portfolio Diversification Support Annaly (NLY) FinancialsPer the Zacks analyst, Annaly's effort to diversify its investment portfolio will provide more stable returns in the days ahead. A decent liquidity position is an added advantage.A Solid Product Portfolio, Focus on R&D Aid Masimo (MASI)The Zacks analyst is upbeat about Masimo's solid product portfolio. Its solid efforts to improve its research and development (R&D) stature is an added plus.New DowngradesSM Energy (SM) to Suffer from Surging Transportation CostsPer the Zacks analyst, SM Energy's transportation costs nearly doubled year over year in fourth-quarter 2024, pressuring margins and potentially straining cash flow if commodity prices stay weak.Elevated Cost Inflation Hurt General Mills (GIS) PerformancePer the Zacks analyst, General Mills is seeing escalated cost inflation. In Q3, the company's adjusted gross margin contracted 60 basis points due to input cost inflation among other reasons.Geopolitical Risks & Pricing Pressure Drag Avanos (AVNS)Per the Zacks analyst, geopolitical tensions, tariffs and FX volatility are raising Avanos Medical's costs, impacting profitability. Growing competition adds pressure, potentially slowing its growth.Zacks Names #1 Semiconductor StockIt's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report The Home Depot, Inc. (HD): Free Stock Analysis Report Manulife Financial Corp (MFC): Free Stock Analysis Report Tesla, Inc. (TSLA): Free Stock Analysis Report iRobot Corporation (IRBT): Free Stock Analysis Report Frequency Electronics, Inc. (FEIM): Get Free Report Bridger Aerospace Group Holdings, Inc. (BAER): Get Free ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks